Navigation Links
PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Date:3/23/2010

269,133 1,225,471 Loss on early extinguishment of debt (4,690,049) - Interest expense (2,837,302) (2,573,406) Other income (expense) (90,655) 58,106 Change in market value of derivative instruments 1,043,782 118,244 --------- ------- Total other income (expenses) (6,305,091) (1,171,585) ---------- ---------- Net loss $(32,279,760) $(36,415,113) ============ ============ Basic and diluted net loss Per share $(1.17) $(1.59) Weighted average shares used in calculation of basic and diluted net loss per share 27,575,332 22,944,066

SOURCE PharmAthene, Inc.

Back to top

RELATED LINKS
http://www.pharmathene.com

'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
2. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
3. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
6. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
9. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
(Date:8/28/2015)... 2015 Research and Markets ... "Global & USA BioSimilar Market Analysis to 2021" ... awaited US Biosimilar market will be initiated in September ... How will the global market react? Will biosimilars explode ... could save the US economy up to $250 billion ...
(Date:8/28/2015)... Dallas, Texas (PRWEB) , ... August 28, 2015 ... ... Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the ... in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... the launch of a suite of miRNA functional ... vector based precursor miRNA expression clones; 2) miTarget(TM) ... 3) All-in-One(TM) miRNA RT-qPCR system.Constructed in a lentiviral ... collections cover all known miRNAs for human ...
... Powerful Multi-Wavelength Workstation Combines Vascular Treatment, Hair ... System- SmartSense(TM) with ThermaGuide(TM): Unique Thermal Sensing ... System for LaserBodyContouring- ThermaView(TM): Thermal Imaging System ... Safety and Control for Optimal Clinical ResultsWESTFORD, ...
... Trusted LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons ... order to provide a resource for consumers seeking to ... who can help improve their chances of attaining 20-20 ... apart is a unique screening process ensuring that only ...
Cached Biology Technology:GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 2Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 3Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 4Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 5Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 2Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 3Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 4Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 5Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 6Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 7
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Although studies of alcohol,s effects on fetal growth have ... on long-term postnatal growth from human studies have been ... heavy prenatal alcohol exposure (PAE) on growth and body ... through to nine years of age, as well as ...
... to a NOAA-led paper published today in the journal ... mainly due to ships, have reduced the ability of ... each other by about two-thirds. From 2007 until ... Lab of Ornithology, NOAA Fisheries Northeast Fisheries Science Center, ...
... - Bureau of Reclamation Commissioner Michael L. Connor ... $1.2 million, and Reclamation will partner with other ... projects to benefit the Desert and Southern Rockies ... to provide more than $3.5 million for these ...
Cached Biology News:Tracking the effects of prenatal alcohol exposure through to 9 years of age 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 3NOAA: Underwater noise decreases whale communications in Stellwagen Bank sanctuary 2WaterSMART funds $1.7 million for science projects in desert and southern Rockies LCCs 2WaterSMART funds $1.7 million for science projects in desert and southern Rockies LCCs 3
ready-to-use solution...
... MS/MS analysis & visualization ... across multiple samples. Combine ... for increased confidence. Get ... information from your MS/MS ...
... Synthetic peptide derived from the N-terminal ... dog and orangutang occludin proteins. ... protein. Reactivity: Human (positive controls: ... rat mouse dog and orangutang is ...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: